Improving Patient Outcomes In Urothelial Carcinoma With Novel Antibody-Drug Conjugates

Improving Patient Outcomes in Urothelial Carcinoma With Novel Antibody–Drug Conjugates

PeerView Oncology

The evolving role of antibody-drug conjugates in the treatment of urothelial carcinoma

Touch Medical Media Services

What’s next for antibody drug conjugates in urothelial carcinoma?

Novel combined ADCs in metastatic urothelial carcinoma: insights from ESMO 2023

Antibody-drug conjugates in urothelial carcinoma

The future of antibody-drug conjugates in urothelial cancer

Biomarkers for novel RCC and urothelial carcinoma treatments

Utilizing antibody-drug conjugates in the treatment of metastatic urothelial carcinoma

Dato-DXd: a new ADC on the block

Antibody Drug Conjugates: The end of chemotherapy | 2023 West Oncology Conference

Total Health | Oncology

Sequencing ADCs and finding novel biomarkers for urothelial carcinoma

New Data on Antibody-Drug Conjugates & Novel Compounds for 2nd-Line Urothelial Carcinoma Treatment

Combining ADC’s with other novel agents in the frontline treatment of urothelial carcinoma

Novel treatment options for patients with metastatic, inoperable urothelial carcinomas

Emerging toxicities associated with ADCs

ADCs in the management of urothelial carcinoma

A novel ADC, AZD5335, for the treatment of solid tumors

Antibody–Drug Conjugates for Solid Tumors: Progress, Possibilities, and Implications for Care

PeerView Oncology

Promising early results of a novel anti-CD123 antibody-drug conjugate in R/R BPDCN

VJHemOnc – Video Journal of Hematology & HemOnc

Novel antibody-drug conjugates (ADCs) technologies for management of mBC